Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Sofia hCG FIA Field Study

NCT01803113 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this field study is to demonstrate the clinical performance of the Sofia hCG FIA Test, using urine specimens from females of childbearing age.

Conditions Studied

Interventions

  • DEVICE Sofia hCG FIA

Study Locations (5)

Massachusetts

  • NECCR of Massachusetts, LLC — Fall River
  • New England Center for Clinical Research Fall River,LLC (NECCR) — Fall River

Florida

  • Jose Castaneda, MD — Boynton Beach

Rhode Island

  • Partners In Obstetrics and Gynecology, Inc. — Pawtucket

Texas

  • Planned Parenthood Gulf Coast — Houston

Trial Details

FieldValue
Enrollment Target 975 participants
Start Date 2013-01
Est. Completion 2013-03

Sponsor

Quidel Corporation

4 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01803113

The ClinicalTrials.gov registry entry for NCT01803113 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quidel Corporation, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Pregnancy, Early Detection appearing as the primary indexed condition, and to 1 intervention — of which Sofia hCG FIA is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01803113 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Massachusetts, Florida, Rhode Island. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01803113 about?

NCT01803113 is a clinical study titled "Sofia hCG FIA Field Study". The objective of this field study is to demonstrate the clinical performance of the Sofia hCG FIA Test, using urine specimens from females of childbearing age.

What is the current status of trial NCT01803113?

This trial is currently completed. The enrollment target is 975 participants. The study started on 2013-01. Estimated completion is 2013-03.

What conditions does trial NCT01803113 study?

This clinical trial studies the following conditions: Pregnancy, Early Detection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01803113?

The interventions under investigation include: Sofia hCG FIA (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01803113?

This trial is sponsored by Quidel Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01803113 being conducted?

This trial has 5 study locations across Florida, Massachusetts, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial